Literature DB >> 12539002

Nitrotyrosine and 8-isoprostane formation indicate free radical-mediated injury in hearts of patients subjected to cardioplegia.

Uwe Mehlhorn1, Andreas Krahwinkel, Hans J Geissler, Karl LaRosee, Uwe M Fischer, Oliver Klass, Michael Suedkamp, Khrosro Hekmat, Paschalis Tossios, Wilhelm Bloch.   

Abstract

OBJECTIVE: Myocardial ischemia and reperfusion induced by cardioplegic arrest subjects the heart to free radical-mediated stress. The purpose of our study was to investigate the effect of cardioplegia-induced ischemia and reperfusion on myocardial formation and distribution of (1) nitrotyrosine as an indicator for peroxynitrite-mediated tissue injury resulting from increased nitric oxide release and (2) 8-isoprostane as an indicator for oxygen-derived free radical-mediated lipid peroxidation.
METHODS: In 10 patients undergoing coronary artery operations (64 +/- 6 [mean +/- SD] years, 3 women and 7 men) subjected to cardiopulmonary bypass and intermittent cold blood cardioplegia, we collected transmural left ventricular biopsy specimens before and at the end of cardiopulmonary bypass. Specimens were cut at 10 micro m and subjected to immunocytochemical staining against the nitric oxide-producing enzyme constitutive nitric oxide synthase, cyclic guanosine monophosphate (intracellular second messenger of nitric oxide), nitrotyrosine, and 8-isoprostane by using polyclonal antibodies. For global left ventricular function determination, we measured the fractional area of contraction using transesophageal echocardiography.
RESULTS: Nitric oxide synthase activity in cardiac myocytes increased from 34 +/- 10 gray units before cardiopulmonary bypass to 47 +/- 12 gray units at the end of bypass (P =.015), and all hearts showed increased cyclic guanosine monophosphate content in both myocytes and endothelial cells at the end of bypass. The number of nitrotyrosine-positive capillaries increased from 36 +/- 29/mm(2) before bypass to 82 +/- 47/mm(2) at the end of bypass (P =.012), and 8-isoprostane-positive capillaries increased from 92 +/- 72/mm(2) before bypass to 209 +/- 108/mm(2) at the end of bypass (P =.005). The fractional area of contraction was 53% +/- 12% before bypass and 56% +/- 12% after bypass (P =.47) but was slightly decreased to 45% +/- 14% at 4 hours after bypass (P =.121).
CONCLUSIONS: Our data show that cardioplegia-induced myocardial ischemia and reperfusion is associated with nitrotyrosine and 8-isoprostane formation mainly in the coronary endothelium, indicating injury mediated by both peroxynitrite and oxygen-derived free radicals. Because nitric oxide synthase activation was accompanied with increased cyclic guanosine monophosphate, these data suggest that direct effects of nitric oxide on cardiac myocytes, as well as nitric oxide-mediated coronary endothelial injury, might contribute to injury associated with cardioplegia and cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12539002     DOI: 10.1067/mtc.2003.97

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  12 in total

1.  Apoptosis during CABG surgery with the use of cardiopulmonary bypass is prominent in ventricular but not in atrial myocardium.

Authors:  W T Ruifrok; B D Westenbrink; R A de Boer; I J den Hamer; M E Erasmus; H E Mungroop; A H Epema; A A Voors; D J van Veldhuisen; W H van Gilst
Journal:  Neth Heart J       Date:  2010-05       Impact factor: 2.380

2.  Controlled reoxygenation cardiopulmonary bypass is associated with reduced transcriptomic changes in cyanotic tetralogy of Fallot patients undergoing surgery.

Authors:  Mohamed T Ghorbel; Amir Mokhtari; Maimuna Sheikh; Gianni D Angelini; Massimo Caputo
Journal:  Physiol Genomics       Date:  2012-09-18       Impact factor: 3.107

Review 3.  Nitrosative stress and pharmacological modulation of heart failure.

Authors:  Pal Pacher; Richard Schulz; Lucas Liaudet; Csaba Szabó
Journal:  Trends Pharmacol Sci       Date:  2005-06       Impact factor: 14.819

Review 4.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

5.  The effects of normoxic versus hyperoxic cardiopulmonary bypass on oxidative stress and inflammatory response in cyanotic pediatric patients undergoing open cardiac surgery: a randomized controlled trial.

Authors:  Massimo Caputo; Amir Mokhtari; Chris A Rogers; Nayia Panayiotou; Qiang Chen; Mohamed T Ghorbel; Gianni D Angelini; Andrew J Parry
Journal:  J Thorac Cardiovasc Surg       Date:  2009-02-23       Impact factor: 5.209

Review 6.  Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.

Authors:  Pal Pacher; Csaba Szabo
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

Review 7.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007

8.  Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.

Authors:  Jacqueline N Minas; Max A Thorwald; Debra Conte; Jose-Pablo Vázquez-Medina; Akira Nishiyama; Rudy M Ortiz
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-11       Impact factor: 2.557

9.  Acute hemodynamic effects of angiotensin- converting enzyme inhibition after prolonged cardiac arrest with Bretschneider's solution.

Authors:  Alexandro Hoyer; Jörg Kempfert; Patrick Pritzwald-Stegmann; Friedrich-Wilhelm Mohr; Stefan Dhein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-10-12       Impact factor: 3.000

10.  Effects of FP15, a peroxynitrite decomposition catalyst on cardiac and pulmonary function after cardiopulmonary bypass.

Authors:  Tamás Radovits; Carsten J Beller; John T Groves; Béla Merkely; Matthias Karck; Csaba Szabó; Gábor Szabó
Journal:  Eur J Cardiothorac Surg       Date:  2012-02       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.